282 related articles for article (PubMed ID: 27507882)
21. Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.
Ghazavi F; De Moerloose B; Van Loocke W; Wallaert A; Helsmoortel HH; Ferster A; Bakkus M; Plat G; Delabesse E; Uyttebroeck A; Van Nieuwerburgh F; Deforce D; Van Roy N; Speleman F; Benoit Y; Lammens T; Van Vlierberghe P
Oncotarget; 2016 Nov; 7(45):73769-73780. PubMed ID: 27650541
[TBL] [Abstract][Full Text] [Related]
22. Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.
Liu YF; Wang BY; Zhang WN; Huang JY; Li BS; Zhang M; Jiang L; Li JF; Wang MJ; Dai YJ; Zhang ZG; Wang Q; Kong J; Chen B; Zhu YM; Weng XQ; Shen ZX; Li JM; Wang J; Yan XJ; Li Y; Liang YM; Liu L; Chen XQ; Zhang WG; Yan JS; Hu JD; Shen SH; Chen J; Gu LJ; Pei D; Li Y; Wu G; Zhou X; Ren RB; Cheng C; Yang JJ; Wang KK; Wang SY; Zhang J; Mi JQ; Pui CH; Tang JY; Chen Z; Chen SJ
EBioMedicine; 2016 Jun; 8():173-183. PubMed ID: 27428428
[TBL] [Abstract][Full Text] [Related]
23. Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.
Quentmeier H; Pommerenke C; Drexler HG
Curr Issues Mol Biol; 2021 Nov; 43(3):2147-2156. PubMed ID: 34940123
[TBL] [Abstract][Full Text] [Related]
24. Analysis of ETV6/RUNX1 fusions for evaluating the late effects of cancer therapy in ALL (acute lymphoblastic leukemia) cured patients.
Brassesco MS; Camparoto ML; Tone LG; Sakamoto-Hojo ET
Cytogenet Genome Res; 2004; 104(1-4):346-51. PubMed ID: 15162063
[TBL] [Abstract][Full Text] [Related]
25. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.
Tange N; Hayakawa F; Yasuda T; Odaira K; Yamamoto H; Hirano D; Sakai T; Terakura S; Tsuzuki S; Kiyoi H
Biomed Pharmacother; 2020 Aug; 128():110330. PubMed ID: 32504922
[TBL] [Abstract][Full Text] [Related]
26.
Sadras T; Müschen M
Blood Cancer Discov; 2020 Jul; 1(1):18-20. PubMed ID: 34661138
[TBL] [Abstract][Full Text] [Related]
27. Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation.
Troeger A; Glouchkova L; Ackermann B; Escherich G; Hanenberg H; Janka G; Roettgers S; Göbel U; Dilloo D
Klin Padiatr; 2014 Nov; 226(6-7):332-7. PubMed ID: 25062112
[TBL] [Abstract][Full Text] [Related]
28. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
Morishita N; Tsukahara H; Chayama K; Ishida T; Washio K; Miyamura T; Yamashita N; Oda M; Morishima T
Pediatr Blood Cancer; 2012 Jul; 59(1):83-9. PubMed ID: 22183914
[TBL] [Abstract][Full Text] [Related]
29. Identifying targets for the restoration and reactivation of BRM.
Kahali B; Gramling SJ; Marquez SB; Thompson K; Lu L; Reisman D
Oncogene; 2014 Jan; 33(5):653-64. PubMed ID: 23524580
[TBL] [Abstract][Full Text] [Related]
30. Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.
Sun K; Chen WM; Wang X; Zhao XS; Li LD; Hao Y; Wang J; Xu N; Jiang Q; Jiang H; Xu LP; Wang Y; Zhang XH; Huang XJ; Qin YZ
Hematol Oncol; 2023 Aug; 41(3):594-597. PubMed ID: 36516881
[No Abstract] [Full Text] [Related]
31. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
32. High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.
Iqbal Z; Akhtar T; Awan T; Aleem A; Sabir N; Rasool M; Absar M; Akram AM; Shammas MA; Shah IH; Khalid M; Taj AS; Jameel A; Alanazi A; Gill AT; Hashmi JA; Hussain A; Sabar MF; Khalid AM; Qazi MH; Karim S; Siddiqi MH; Mahmood A; Iqbal M; Saeed A; Irfan MI
Mol Diagn Ther; 2015 Oct; 19(5):277-87. PubMed ID: 26266519
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.
Moreno DA; Scrideli CA; Cortez MA; de Paula Queiroz R; Valera ET; da Silva Silveira V; Yunes JA; Brandalise SR; Tone LG
Br J Haematol; 2010 Sep; 150(6):665-73. PubMed ID: 20636436
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia.
Tanaka Y; Kawazu M; Yasuda T; Tamura M; Hayakawa F; Kojima S; Ueno T; Kiyoi H; Naoe T; Mano H
Haematologica; 2018 Nov; 103(11):e522-e526. PubMed ID: 29773604
[No Abstract] [Full Text] [Related]
35. Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.
Messina M; Chiaretti S; Wang J; Fedullo AL; Peragine N; Gianfelici V; Piciocchi A; Brugnoletti F; Di Giacomo F; Pauselli S; Holmes AB; Puzzolo MC; Ceglie G; Apicella V; Mancini M; Te Kronnie G; Testi AM; Vitale A; Vignetti M; Guarini A; Rabadan R; Foà R
Oncotarget; 2016 Mar; 7(12):13886-901. PubMed ID: 26883104
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
37. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
38. Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
Perwein T; Strehl S; König M; Lackner H; Panzer-Grümayer R; Mann G; Attarbaschi A; Urban EC; Haas OA
Haematologica; 2016 Aug; 101(8):e332-5. PubMed ID: 27125982
[No Abstract] [Full Text] [Related]
39. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
40. [Usefulness of molecular screening in childhood lymphoblastic leukemias].
Anguita E; González FA; Contra T; Martín N; Valverde F; Villegas A
Sangre (Barc); 1998 Feb; 43(1):7-11. PubMed ID: 9577176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
